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Cardiolipinuent impairment of mitochondrial function is implicated in the neurodegen-
erative process and hence in diseases such as Parkinson's and Alzheimer's disease. Within the brain, neuronal
and astroglial cells can display a differential susceptibility to oxidant exposure. Thus, astrocytes can up
regulate glutathione availability and, in response to mitochondrial damage, glycolytic ﬂux. Whilst neuronal
cells do not appear to possess such mechanisms, neuronal glutathione status may be enhanced due to the
trafﬁcking of glutathione precursors from the astrocyte. However, when antioxidants reserves are not
sufﬁcient or the degree of oxidative stress is particularly great, mitochondrial damage occurs, particularly at
the level of complex IV (cytochrome oxidase). Whilst the exact mechanism for the loss of activity of this
enzyme complex is not know, it is possible that loss and/or oxidative modiﬁcation of the phospholipid,
cardiolipin is a critical factor. Consequently, in this short article, we also consider (a) cardiolipin metabolism
and function, (b) the susceptibility of this molecule to undergo oxidative modiﬁcation following exposure to
oxidants such as peroxynitrite, (c) loss of mitochondrial cardiolipin in neurodegenerative disorders, (d)
methods of detecting cardiolipin and (e) possible therapeutic strategies that may protect cardiolipin from
oxidative degradation.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Oxidative stress, arising from reactive oxygen or nitrogen species
(ROS or RNS), has been implicated in the pathogenesis of neurode-
generative disorders such as Parkinson's (PD) and Alzheimer's disease
(AD) (Reviewed in [1]). Furthermore, loss of mitochondrial function, at
the level of the electron transport chain (ETC) is also associated with
the neurodegenerative process [1]. Consequently, in view of the
susceptibility of the ETC to oxidative damage, loss of ETC activity, due
to oxidant exposure, has been proposed to be a plausible mechanism
for the neuronal cell death associated with PD, AD and other neuro-
degenerative conditions [1]. In view of this, a number of therapeutic
strategies have been proposed, largely involving the use of antiox-
idants, in an attempt to prevent the oxidative inactivation of the ETC
and thus limit neuronal cell death [1]. Unfortunately, to date, clinical
trials reveal limited efﬁcacy and so this may suggest the need for
better delivery of antioxidant molecules to brain cells and/or their
mitochondria. Alternatively, new vulnerable molecules, essential for
mitochondrial function, may need to be identiﬁed that could provide
new therapeutic targets. One suchmolecule is cardiolipin (CL) and thisr Neuroscience, Institute of
K. Tel.: +44 845 155 5000x73
ll rights reserved.short article will review brain oxidative stress/mitochondrial dysfunc-
tion (within the context of neurodegeneration) and how potential
alterations in functional CL may contribute to an impairment of the
ETC.
2. Oxidative stress and energy metabolism in neurones
and astrocytes
The brain is particularly dependent on mitochondrial energy
supply to maintain normal function. Whist the individual components
of the electron transport chain exhibit varying degrees of sensitivity
towards ROS and RNS, it appears that neuronal and astrocytic cells can
display a differential response to an ETC that has a compromised
ability to generate ATP [2].
With regards to astrocytes, inhibition of mitochondrial ATP
generation results in a preservation of cellular energy status due to
a stimulation of glycolysis. Such an up regulation of glycolysis appears
to be mediated through the AMP protein kinase and 6-phosphofructo-
2-kinase pathway (PFK2) [3]. In direct contrast, neuronal cells have a
virtual absence of PFK2 and hence are particularly sensitive to failure
of mitochondrial oxidative phosphorylation [3].
In addition to exhibiting a differential response to mitochondrial
dysfunction, antioxidant status, in particular reduced glutathione
(GSH)metabolism, appears different between astrocytes and neuronal
cell. Data derived largely from cell culture studies reveal that the GSH
Fig. 2. Synthesis of cardiolipin in eukaryotes. After synthesis of cytidinediphosphate-
diacylglycerol (CDP-DAG) from phosphatidic acid, CL synthesis consist of three steps,
which all take place in the inner mitochondrial membrane. The ﬁrst step is the
formation of phosphatidylglycerophosphate (PGP) from CDP-diacylglyceol and glycerol
3-phosphate by PGP synthase. In the second step, PGP is dephosphorylated by PGP
phosphatase to produce phosphatidylglycerol (PG). In the ﬁnal step, catalysed by CL
synthase, PG is combined with CDP-diacyglycerol to form CL.
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compared to neuronal cells [2]. Such a discrepancy can be attributed to
a greater speciﬁc activity, within astrocytes, of the rate limiting
enzyme for GSH biosynthesis, glutamate cysteine-ligase (GCL) [4].
When compared to astrocytes, neurones can display marked
sensitivity to RNS. However, vulnerability appears to be diminished
when neurones are co-cultured with astrocytes [5]. Such protection
appears to arise as a result of an increase of neuronal GSH availability
[5]. This increase in GSH content occurs as a consequence of the
trafﬁcking of GSH precursors from astrocytes to neurones. Prevention
of this trafﬁcking results in the failure of the neuronal cells to up-
regulate their GSH status and renders the ETC susceptible to damage
by RNS [6].
Under conditions where the activity of the ETC is irreversibly
compromised, complex IV (cytochrome oxidase) appears, with regards
to neural cells, to be a particularly susceptible to RNS exposure and/or
GSH depletion [6–8]. Whilst the exact mechanism for this loss of
complex IV activity is not known, it is possible, in view of the particular
requirement of this enzyme for cardiolipin (see below), that oxidative
modiﬁcation of this phospholipid is a contributing factor. Support for
this suggestion may come from our previous studies that demonstrated
that Trolox, a vitamin E analogue and hence potential inhibitor of lipid
peroxidation, was superior, when compared to other antioxidants, at
preventing complex IV damage following RNS exposure [9].
3. Cardiolipin
Cardiolipin (CL) is a dimeric phospholipid with an unusual
structure consisting of four acyl side chains in comparison to more
typical lipids which have two acyl chains [10] (Fig. 1). In eukaryotes, CL
is found almost exclusively in the mitochodrial inner membrane,
where it accounts for ~25% of all mitochondrial lipids [11]. In the innerFig. 1. Structure of cardiolipin with four linoleic acid side chains. This form is typically
designated as CL(18:2)4 indicating the length and number of double bonds in each
carbon side chain.membrane, CL is distributed approximately 60:40 between the matrix
and intermembrane space [12,13].
CL is synthesised from phosphatidic acid via a number of enzymatic
steps (Fig. 2) [10].Whilst the initial steps of CL synthesis are comparable
to that of other phospholipids, the ﬁnal reaction, catalysed by CL
synthase is unique [10]. The mitochondrial inner membrane itself
contains all the enzymes of the CLpathwaydownstreamof phosphatidic
acid, the latter being synthesised in the outer mitochondrial membrane
[10]. CL biosynthesis, thoughnot fully characterised, appears to behighly
regulated. For instance, there is an apparent strong dependence on the
intracellular concentration of cytidine triphosphate and ATP [10]. In
addition, the CL pathway is integrally related to mitochondrial devel-
opment and complex IV assembly [10]. Although the fatty acid side
chains of CL precursors may vary considerably, in mature CL the fatty
acid side chains are usually symmetrical and contain a single type of
fatty acid [14]. In most mammalian tissue (heart, skeletal muscle, liver
and kidney) the predominant form of CL is tetralinoleoyl CL— CL(18:2)4
[14,15]. However, there is somevariation in side chain composition of CL,
with testes containing high levels C16:0 [15] and brain containing high
levels of polyunsaturated side chains such as C20:4 and C22:6 [16–18].
The remodelling of the acyl side chains is not fully understood, but the
structural conformity and symmetry of the resulting CL molecules is
postulated to be important for different biological functions [14].
4. CL and mitochondria
CL is an integral part of the mitochondrial inner membrane and is
associated with many mitochondrial proteins. Therefore it has always
been assumed to have an important role in mitochondrial function.
However, it is only relatively recently that deﬁned functions of CL have
been proposed. Studies of mutant cells deﬁcient in CL provided some
of the ﬁrst insights into the role of CL in mitochondria. In yeast
mutants, lacking functional CL synthase, no CL is present in the
mitochondrial membranes and these cells lose viability at elevated
temperatures. When grown on glucose, these mutants show reduced
respiratory rate, deﬁcient ATPase and complex IV activities plus
impairment of the ADP–ATP translocator [19].
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studies of CL deﬁciency in mammalian cells were performed on
Chinese hamster ovary cells lacking a functional PGP synthase, which
synthesises a direct precursor to CL (Fig. 2). As a consequence, these
cells display reduced levels of CL, altered mitochondrial morphology,
reduced ATP concentrations, diminished oxygen consumption and
defective ETC activity [20].
Further insights into the role of CL in human cells have beenobtained
fromthe studyofpatientswithBarth syndrome, inwhichCLmetabolism
is affected. Barth syndrome is an X-linked disease characterised by
cardiomyopathy, neutropenia,muscleweakness and a loss ofmitochon-
drial function [21]. This disorder arises from a defect in the TAZ gene,
which codes for a group of proteins called the tafazzins, produced by
alternative splicing [22]. The tafazzins are phospholipid acyltransferases
involved in CL remodelling [23]. Patients with Barth's syndrome exhibit
a loss of functional CL, in particular the tetralinoleoyl form, in a variety of
tissues [24]. They also exhibit an increase in monolysocardiolipins (CL
missing an acyl chain) [24].
A direct role of tafazzin in CL metabolism has also been shown in
yeast, where yeast expressing the TAZ mutation exhibit a decrease in
normal CL species containing C18:1 and C16:1 fatty acids, an increase
in monolysocardiolipin [25] and destabilisation of respiratory chain
complexes [26]. Incubation of ﬁbroblasts from patients with Barth
syndrome with linoleic acid leads to an increase in tetralinoleoyl CL
content [27], but the effects of this treatment in patients await further
investigation.
Of the associations between mitochondrial enzymes and CL, the
interaction betweenCL and complex IV is perhaps the best documented.
Thus, eachmonomer of the complex is known to bind twomolecules of
CL [28] and loss of CL results in lowactivity. However, activity of puriﬁed
enzyme can be restored with CL(18:2)4 but not variants such as
dilysocardiolipin (CL with only two acyl groups) [29], CL containing two
C6 chains [29] or, in the case of heart mitochondria, peroxidised CL [30].
A number ofmodels have beenproposed in order to explain the effect of
CL on complex IV activity. These include; (a). CL acts to increase the
surface concentration of cytochrome c, (b). CL increases the surface
concentrationof protons, (c). CL brings about a conformational change of
the enzyme that enhances catalytic activity [31].
The effects of CL upon ETC function are not conﬁned to complex IV,
i.e. complexes I and III also bind CL and display low activity in its
absence. Furthermore, CL facilitates the association of complex III and
IV into “supercomplexes”. Such supercomplex formation is thought to
improve the efﬁciency of oxidative phosphorylation by eliminating
the need for diffusion of substrates and products between the
individual ETC components [32].
In addition to effects upon the ETC, CL interacts with the ADP–ATP
translocator. Puriﬁed ADP–ATP carrier from bovine heart contains six
molecules of tightly bound CL per protein dimer and these CLs canFig. 3. The effect of peroxynitrite and antioxidants on oxidised cardiolipin levels in muscle
absence of peroxynitrite (Peroxy) (1 mM)±Trolox (2.5 mM) or GSH (2 mM). After incubation
(n=3–6). Lipid extraction and LC-MS analysis were carried out as previously described by V
monitoring (MRM) mode as a transition from 723N279. Oxidised cardiolipin was measured
Collision 30; Cone 25 V.). (C14:0)4-CL was used as an internal standard.only be removed under denaturing conditions [33]. These CLs appear
to act as a prosthetic group for the protein and removal of these CLs
results in the loss of carrier function [34].
5. The interaction of CL with cytochrome C and its role in apoptosis
Recentﬁndings havedemonstrated that CL and itsmetabolites have
key roles in the apoptotic cell death program [35]. At the early stages of
apoptosis, CL is redistributed to the outer monolayer of the
mitochondrial inner membrane and the outer mitochondrial mem-
brane [13,36,37]. Redistribution of CL is likely to occur via interactions
with apoptosis-associated proteins such as Bid/tBid and Bax at contact
sites between the inner and outer membranes [38,39]. tBid, the
truncated formof Bid, displays a high afﬁnity formonolysocardiolipins,
formed during the remodelling of CL. Since acyl chain remodelling of
CL occurs outside the mitochondria, Bid and tBid have been proposed
to have a role in the normal metabolic cycle of CL [40].
Redistribution enables signiﬁcant amounts of CL to interact with
cytochrome C in the intermembrane space. The cytochrome C–CL
complex formed can act as a potent peroxidase in the presence of
hydrogen peroxide leading to the formation of CL hydroperoxides and
release of cytochrome C [13]. Release of cytochrome C from the
mitochondria is a key feature of apoptosis [41] and decreases in CL
content [42] or increases in CL peroxidation [43–45] have been
associated with liberation of cytochrome C from the mitochondrion
and subsequent tissue degeneration. However, release of cytochrome
C is not the only role CL hydroperoxides have in apoptotis, since the
addition of exogenous CL hydroperoxides to cytochrome C deﬁcient
cells is sufﬁcient for the release of other pro-apoptotic factors such as
Smac/Diablo [13].
Oxidation of CL may also trigger the remodelling pathway
involving Bid [35]. It has been hypothesised that oxidised side chains
of CL are hydrolysed in the inner membrane by phospholipase A2 and
monolysocardiolipin produced is subsequently transported by Bid to
the ER for remodelling [35].
6. CL in the brain
Unlike themajority ofmammalian tissues, tetralinoleoyl CL is not the
predominant formof CL in the brain. Inmouse brain, stearic (18:0), oleic
(18:1), cervonic (22:6) and arachidonic acid (20:4) each contribute to
about 20% of acyl side chains of CL [46]. In contrast, linoleic acid (18:2)
contributes to less than 5% of acyl side chains [16,17]. The reason for this
difference in CL side chain between brain and other tissue is not known.
However, this difference in fatty acid composition could render brain CL
more susceptible to peroxidation, i.e. due to the higher double bond
content of the acyl side chains. Support for this suggestion comes from
studies using HL60 cells that have been engineered to contain morehomogenates. Pooled muscle homogenates were incubated for 3 h in the presence or
, lipids were extracted and unoxidised and oxidised cardiolipin was measured by LC-MS
alianpour et al., 2002 [55]. Unoxidised cardiolipin was measured in multiple reaction
as a transition from 731N279. (Mass spectrometer settings:Negative ion mode −3.3 kV;
797S. Pope et al. / Biochimica et Biophysica Acta 1777 (2008) 794–799C22:6 CL species. These cells display increased sensitivity to apoptotic
stimuli, in comparison to wild-type cells that contain predominantly
C16:0 and C18:2 CL species [13].
As is the case for GSH metabolism and the ability to invoke a
glycolytic response following ETC damage (see above), brain CL status
also appears to be heterogeneous. Thus, synaptic and non-synaptic
mitochondria vary in their CL content and display a differential effect
with regards to the effects of ageing [47].
With regards to oxidative stress and neurodegeneration a number
of experimental models support the concept of loss of functional brain
CL. Thus, studies upon aged rat brain report CL depletion, loss ofFig. 4. A. Cardiolipin hydroperoxide. B. The main oxidised cardiolipin specie observed in the e
293. This oxidised product was probably the result of decay of cardiolipin hydroperoxide, wcomplex IV activity and mitochondrial membrane potential. Similarly,
models of traumatic brain injury, familial amytrophic lateral sclerosis
(mice over expressing superoxide dismutase) and Parkinson's disease
(mice lacking alpha synuclein) report CL deﬁciency, increased lipid
peroxidation and loss of ETC activity [16,46,48].
7. CL oxidation
As indicated above, CL is particularly susceptible to oxidation
because (1) it contains easily oxidised unsaturated side chains, such as
linoleic acid or docosahexanoic acid (cervonic acid) and (2) it isxperiment detailed in Fig. 3 had amolecular ion of m/z 731 and fragment ions of 279 and
ith loss of water, during analysis.
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Therefore there is currently growing interest in identifying and mea-
suring oxidised CL species.
Classical lipid peroxidation proceeds via the following steps; (1)
abstraction of a hydrogen, forming an alkyl radical, (2) addition of
oxygen, to form a peroxy radical, (3) formation of a hydroperoxide via
abstraction of a hydrogen from another lipid chain (thereby continu-
ing lipid peroxidation) or from an antioxidant such α-tocopherol/
trolox. CL oxidation is considered to proceed in a similar manner so
the main products are cardiolipin hydroperoxides (CLOOH), contain-
ing varying numbers of oxygens.
When considering CL oxidation, preliminary data from our own
laboratory (Figs. 3 and 4) and that of others [16,49–51] reveal that
numerous oxidised products may be produced. The nature of these
species may depend upon the site and extent of oxidation, as well as
on the breakdown of the oxidised species to secondary oxidation
products (Fig. 4). The complexity and range of products formed,
following exposure of CL to oxidants such as ONOO−, illustrates the
need to deﬁne exactly which oxidised species are being generated.
This may be of particular importance as different CL oxidation
products could potentially exert differing biological effects.
8. Measurement of CL
CL and oxidised CL have been measured by a variety of techniques.
These includeHPLC [52], thin layer chromatography (TLC), nonyl acridine
orange (NAO) binding and liquid chromatography with mass spectro-
metry (LC-MS) [53–57]. Thesemethods vary in sensitivity and speciﬁcity,
e.g. NAO in addition to reﬂecting CL status also responds to the mito-
chondrial membrane potential [57]. For simple chemical systems
assessing CL oxidation, UV detection of conjugated dienes or TLC may
be sufﬁcient. However, for complicated biological samples, a sensitive
technique such as LC-MS, which is able to distinguish the various
oxidised forms of CL from other lipids, would be the method of choice.
9. Potential therapeutic strategies to prevent CL oxidation
In view of the sensitivity of CL to RNS and ROS, antioxidants may
have a role in preventing CL oxidation. Preliminary data from our
laboratory support this suggestion by demonstrating that Trolox and
GSH are both capable of retarding ONOO-mediated oxidation [Fig. 3].
However, such ﬁndings were performed upon tissue homogenates
and whilst providing a useful proof of principle, targeting to the
mitochondria may be required for intact cellular systems and in vivo.
Thus, molecules such as MitoQ and MitoE (ubiquinone and vitamin E
homologues respectively), which target and accumulate within
mitochondrial membranes [58], could prove to be particularly
effective at preventing CL oxidation in appropriate cellular and in
vivo model systems.
10. Conclusion
There is now a growing body of evidence to implicate oxidative
stress and mitochondrial dysfunction in the pathogenesis of neuro-
degenerative disorders. However, it also now clear that different brain
cell types, namely astrocytes and neurones, can have differing
antioxidant reserves and metabolic responses to a compromised
ETC. Appreciation of such differences may be important when
considering new therapeutic strategies to combat the neurodegen-
erative process. Similarly, new targets susceptible to oxidation will
continue to be identiﬁed that if their degradation could be prevented
may form the basis of new treatment regimes. One such molecule
appears to be CL and it now becoming clear that this phospholipid
plays a critical role in maintaining optimal ETC function and
controlling apoptosis. However, the nature of the acyl side chains
can render this molecule vulnerable to oxidative damage with aconsequential loss of biological function. Further work is therefore
required to identify CL status and the nature of any oxidised
degradation products in a range of appropriate model systems and
human biopsy material. Such data may then provide the basis for
drugs that can speciﬁcally prevent loss of functional CL from the
mitochondrial inner membrane.
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